Can Female Carriers of Fabry Disease Have Severe Symptoms?
At a Glance
Yes, female "carriers" of Fabry disease can experience severe symptoms. The term "carrier" is outdated. Due to X-chromosome inactivation, women can lack the necessary enzyme in specific organs, leading to heart, kidney, and nerve issues that require the same monitoring and treatment as men.
Yes. In fact, the medical community now recognizes that the term “carrier” is outdated and misleading when it comes to females with Fabry disease [1]. Historically, doctors believed that because Fabry disease is an X-linked genetic condition, women were just carriers who passed the gene to their children without experiencing symptoms themselves [1]. We now know this is a myth: females with the Fabry gene are affected patients who can develop symptoms just as severe as men’s [2][1].
If you have been told you are just a “carrier” but are feeling sick, your symptoms are real, valid, and have a clear biological explanation [2][3].
The Biology: Why Females Get Sick (Lyonization)
To understand why females develop severe symptoms, we have to look at how X chromosomes work. Fabry disease is caused by a genetic change on the X chromosome, which prevents the body from making enough of a crucial enzyme called alpha-galactosidase A [4]. Without this enzyme, fatty substances build up in your cells.
Men have one X chromosome and one Y chromosome. If their one X chromosome has the Fabry mutation, all of the cells in their body lack the enzyme, leading to disease [5].
Women have two X chromosomes—one inherited from each parent. In females with Fabry disease, one X chromosome has the mutation, and the other is healthy [3]. However, the female body does not need both X chromosomes to be active at the same time. To balance things out, the body randomly “turns off” or silences one X chromosome in every single cell very early in embryonic development [6][7]. This process is called X-chromosome inactivation or Lyonization [6].
Because this silencing happens randomly, every woman’s body becomes a mosaic [4]. In some of your cells, the healthy X chromosome is active, and those cells make the enzyme normally. In other cells, the mutated X chromosome is active, and those cells cannot make the enzyme [8].
The “Luck of the Draw” in Your Organs
Whether a female experiences mild, moderate, or severe symptoms depends heavily on this random X-chromosome inactivation [9][10].
- If the healthy X chromosome happens to stay active in the majority of your cells, you might have very mild symptoms or no symptoms at all.
- If the X chromosome with the Fabry mutation is active in a large percentage of your cells, you will lack the enzyme in those tissues and develop significant symptoms [8].
Importantly, this inactivation pattern can differ from organ to organ [8]. For example, a woman might have mostly healthy cells in her kidneys, but a high percentage of Fabry-affected cells in her heart or nervous system. As a result, she could have severe heart problems or nerve pain even with normal kidney function [8].
Because of this tissue-dependent mosaic effect, female patients often have normal or near-normal enzyme levels on standard blood tests [11]. Those blood tests cannot reliably predict how severely your specific organs are affected, which is why a genetic test—rather than just an enzyme test—is required to properly diagnose you [11].
What This Means for Your Care
Because of X-chromosome inactivation, your disease course is unique [12]. While women’s symptoms sometimes start later in life than men’s, they are no less real and can lead to the exact same severe complications, including heart, kidney, and cerebrovascular issues [13][14].
Because you are an affected patient, not an unaffected carrier, you require the same level of care as a male patient [1]. This means:
- Routine Organ Monitoring: You need regular checkups to monitor your organs for early signs of damage, regardless of how you currently feel [12]. This includes specific tests like an echocardiogram or cardiac MRI for your heart, urine tests for protein (proteinuria) to check your kidneys, and neurological evaluations.
- Access to Treatment: Females qualify for and benefit from the exact same Fabry-specific treatments as men, such as enzyme replacement therapy (ERT) or oral chaperone therapy (like migalastat), which can stabilize organ function [14][15].
- Symptom Management: Your symptoms should be treated aggressively to improve your quality of life. For instance, there are specific medications to treat the severe burning pain in the hands and feet (acroparesthesia) and strategies to help manage the inability to sweat or gastrointestinal issues.
- Genetic Counseling and Family Testing: Because Fabry is an X-linked genetic condition, evaluating at-risk relatives is a crucial part of the care pathway. A genetic counselor can help you understand what this means for your children and extended family.
Do not let the label of “carrier” stop you from getting the medical attention you deserve [1][16].
Common questions in this guide
Are women with Fabry disease just carriers?
Why do females with the Fabry gene get symptoms?
Why are my enzyme blood tests normal if I have Fabry symptoms?
Do female Fabry patients need regular organ monitoring?
What treatments are available for females with Fabry disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Can you refer me to a specialist who has experience treating symptomatic females with Fabry disease?
- 2.What specific baseline tests—like an echocardiogram, cardiac MRI, or urine protein test—should we run to check my organ function?
- 3.Based on my current symptoms and genetic mutation, am I a candidate for enzyme replacement therapy or chaperone therapy?
- 4.What medications or therapies can we try to manage the burning pain in my hands and feet?
- 5.Can you refer me to a genetic counselor to discuss testing for my children or other family members?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (16)
- 1
Fabry disease phenotyping in women from the complete Romanian cohort - time for early diagnostic awareness.
Mursă A, Militaru S, Rusu E, et al.
Romanian journal of internal medicine = Revue roumaine de medecine interne 2024; (62(4)):414-429 doi:10.2478/rjim-2024-0027.
PMID: 39182239 - 2
Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation.
Selthofer-Relatic K
Case reports in cardiology 2018; (2018()):6131083 doi:10.1155/2018/6131083.
PMID: 29755794 - 3
Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M, Brand E
Journal of the American Society of Nephrology : JASN 2018; (29(9)):2265-2278 doi:10.1681/ASN.2018030329.
PMID: 30093456 - 4
Clinical management of female patients with Fabry disease based on expert consensus.
Brand E, Linhart A, Deegan P, et al.
Orphanet journal of rare diseases 2025; (20(1)):7 doi:10.1186/s13023-024-03500-7.
PMID: 39773286 - 5
The role of two dimensional speckle tracking echocardiography in determining cardiac prognosis and monitoring enzyme replacement therapy efficacy in patients with Anderson-Fabry disease.
Nabati M, Parsaee H
Journal of clinical ultrasound : JCU 2024; (52(1)):30-31 doi:10.1002/jcu.23612.
PMID: 38053509 - 6
BAF complex-mediated chromatin relaxation is required for establishment of X chromosome inactivation.
Keniry A, Jansz N, Gearing LJ, et al.
Nature communications 2022; (13(1)):1658 doi:10.1038/s41467-022-29333-1.
PMID: 35351876 - 7
X chromosome inactivation in human development.
Patrat C, Ouimette JF, Rougeulle C
Development (Cambridge, England) 2020; (147(1)) doi:10.1242/dev.183095.
PMID: 31900287 - 8
Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.
Rodríguez Doyágüez P, Furlano M, Ars Criach E, et al.
Nefrologia 2023; (43 Suppl 2()):91-95 doi:10.1016/j.nefroe.2024.01.018.
PMID: 38278716 - 9
X-chromosome inactivation in female patients with Fabry disease.
Echevarria L, Benistan K, Toussaint A, et al.
Clinical genetics 2016; (89(1)):44-54 doi:10.1111/cge.12613.
PMID: 25974833 - 10
Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.
Izhar R, Borriello M, La Russa A, et al.
Genes 2023; (15(1)) doi:10.3390/genes15010037.
PMID: 38254927 - 11
X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis.
Viggiano E, Politano L
International journal of molecular sciences 2021; (22(14)) doi:10.3390/ijms22147663.
PMID: 34299283 - 12
Fabry disease revisited: Management and treatment recommendations for adult patients.
Ortiz A, Germain DP, Desnick RJ, et al.
Molecular genetics and metabolism 2018; (123(4)):416-427 doi:10.1016/j.ymgme.2018.02.014.
PMID: 29530533 - 13
Fabry disease in female monozygotic twins with complex intronic haplotype variants: a case report.
Choi HS, Kwon OI, Kim SS, et al.
BMC medical genomics 2024; (17(1)):245 doi:10.1186/s12920-024-02021-3.
PMID: 39375654 - 14
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.
Müntze J, Gensler D, Maniuc O, et al.
Clinical pharmacology and therapeutics 2019; (105(5)):1224-1233 doi:10.1002/cpt.1321.
PMID: 30506669 - 15
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA, Nicholls K, Shankar SP, et al.
Journal of medical genetics 2017; (54(4)):288-296 doi:10.1136/jmedgenet-2016-104178.
PMID: 27834756 - 16
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ, Cabrera G, Charrow J, et al.
Molecular genetics and metabolism 2016; (119(1-2)):151-9.
PMID: 27510433
This page provides educational information about Fabry disease in females. It does not replace professional medical advice; always consult a Fabry specialist or genetic counselor regarding your symptoms and treatment.
Get notified when new evidence is published on Fabry disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.